Complete Histologic Remission after Sunitinib Neoadjuvant Therapy in T3b Renal Cell Carcinoma

European Urology

Volumn 55, Issue 6, 2009, Pages 1477-1480

  Robert, Grégoire ^a,b   Gabbay, Grégoire ^a   Bram, Raphaël ^a,b   Wallerand, Hervé ^a,b   Deminière, Colette ^a,b   Cornelis, François ^a   Bernhard, Jean Christophe ^a   Ravaud, Alain ^a,b   Ballanger, Philippe ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Locally advanced; Neoadjuvant; RCC; Renal cancer; Sunitinib; Thrombus; Tyrosine kinase inhibitors

Indexed keywords

SUNITINIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE;

ADJUVANT THERAPY; AGED; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CASE REPORT; CAVA VEIN THROMBOSIS; FEMALE; FLANK PAIN; HISTOLOGY; HUMAN; KIDNEY CARCINOMA; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PERCUTANEOUS BIOPSY; PRIORITY JOURNAL; SHORT SURVEY; THROMBECTOMY; THROMBOCYTOPENIA; TREATMENT REFUSAL; TREATMENT RESPONSE; TUMOR NECROSIS; TUMOR VOLUME; VEIN THROMBOSIS; ARTICLE; CANCER STAGING; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; METHODOLOGY; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; TREATMENT OUTCOME;

AGED; BIOPSY, NEEDLE; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEPHRECTOMY; PROTEIN KINASE INHIBITORS; PYRROLES; TREATMENT OUTCOME;

EID: 66249097161     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.12.036     Document Type: Short Survey

References (7)

1. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
2. Amin C., Wallen E., Pruthi R.S., Calvo B.F., Godley P.A., and Rathmell W.K. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72 (2008) 864-868
3. Shuch B., Riggs S.B., LaRochelle J.C., et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 102 (2008) 692-696
4. Karakiewicz P.I., Suardi N., Jeldres C., et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 53 (2008) 845-848
5. Ljungberg B., Hanbury D.C., Kuczyk M.A., et al. Renal cell carcinoma guideline. Eur Urol 51 (2007) 1502-1510
6. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
7. Ravaud A., Wallerand H., Culine S., et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 54 (2008) 315-325